Clinical trials: Low Grade Gliomas
Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption. Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide…
- Trial name
- ExCentric (NCT01124240)
- Testing
- Cilengitide
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Northern Sydney and Central Coast Area Health Service
Low Grade Astrocytoma, Low Grade Glioma
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that…
- Conditions
- Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
- Trial name
- NCT04166409
- Testing
- Biospecimen Collection, Carboplatin, Echocardiography Test
- Where
- 132 sites in United States, Canada and 1 more
- Volunteers
- 170 people
- Sponsor
- National Cancer Institute (NCI)
Low-grade Glioma
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
The purpose of this study is to investigate whether weekly Vinorelbine treatment can shrink or slow the growth of pediatric low-grade gliomas that have either returned or are continuing to grow.
- Trial name
- NCT01497860
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Eugene Hwang
Low-Grade Astrocytoma, Nos
Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
RATIONALE: Current therapies for adult recurrent/progressive low grade astrocytoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment…
- Trial name
- NCT00003471
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Burzynski Research Institute
Refractory Cancer, CNS Tumors
A Study of Avutometinib for People With Solid Tumor Cancers
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults.
- Conditions
- Refractory Cancer, CNS Tumors, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- NCT06104488
- Testing
- Avutometinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Low-grade Glioma
DAY101 In Gliomas and Other Tumors
This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments.
- Trial name
- NCT03429803
- Testing
- DAY101
- Where
- 15 sites in United States
- Volunteers
- 44 people
- Sponsor
- Karen D. Wright, MD
Low-grade Glioma, Meningioma
FG001 in Subjects with Meningiomas or Presumed Low-Grade Gliomas Scheduled for Neurosurgery
In neurosurgery both the diffusely infiltrated gliomas of the brain as well as the border towards healthy tissue in the meninges is a challenge.
- Conditions
- Low-grade Glioma, Meningioma, Glioma
- Trial name
- NCT06684795
- Testing
- FG001 prior to surgery
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas
The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
- Conditions
- Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
- Trial name
- NCT01130077
- Testing
- HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- James Felker
Brain Neoplasm, Low Grade Glioma
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or…
- Conditions
- Brain Neoplasm, Low Grade Glioma, Seizure Disorder
- Trial name
- NCT04553757
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Glioma
Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
Optico-chiasmatic gliomas have therapeutic feature since surgical resection plays a secondary role. Unlike other sites, many of these tumors are not amenable to complete resection either because of anatomical location, and…
- Trial name
- FLUVABREX (NCT02115074)
- Testing
- Fluvastatine, Celebrex
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Oscar Lambret
Glioma
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.
- Trial name
- NCT03343197
- Testing
- AG-120, AG881
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Institut de Recherches Internationales Servier
Low-grade Glioma, Temozolomide
Trial in Low Grade Glioma Patients: Wait or Treat
The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment.
- Conditions
- Low-grade Glioma, Temozolomide, Phase III, Wait or Treat
- Trial name
- IWOT (NCT03763422)
- Testing
- Temozolomide, Radiotherapy, Surgery
- Where
- 45 sites in Australia, Austria and 8 more
- Volunteers
- 19 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00114140
- Testing
- Temozolomide, Radiation therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Tumors, Central Nervous System Tumors
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctors to give higher doses…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00003141
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 71 sites in United States, Australia and 1 more
- Volunteers
- 94 people
- Sponsor
- Children's Oncology Group
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
- Conditions
- Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma
- Trial name
- NCT02175745
- Testing
- 18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Erik Mittra
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors.
- Conditions
- Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma
- Trial name
- NCT01837862
- Testing
- Mebendazole, Vincristine, Carboplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Julie Krystal
Low-grade Diffuse Glioma
Molecular Heterogeneity in Multilobar Low-grade Gliomas
Low-grade diffuse glioma (GDBG) are rare tumors of young adults, whose ontogenesis is poorly understood. Patient management is based on the molecular profile defined by two molecular markers : mutations of the IDH genes and…
- Trial name
- NCT04000048
- Testing
- sequencing of the complete exome
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Montpellier
Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation
Proton Radiation Therapy for Gliomas
In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal…
- Conditions
- Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation, WHO Grade 3 Glioma With 1p/19q Codeletion
- Trial name
- NCT01358058
- Testing
- Proton radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Massachusetts General Hospital